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Abstract
Despite its apparently simple genetics, cystic fibrosis 
(CF) is a rather complex genetic disease. A lot of varia-
bility in the steps of the path from the cystic fibrosis 
transmembrane conductance regulator (CFTR ) gene 
to the clinical manifestations originates an uncertain 
genotype - phenotype relationship. A major determinant 
of this uncertainty is the incomplete knowledge of 
the CFTR mutated genotypes, due to the high number 
of CFTR mutations and to the higher number of their 
combinations in trans  and in cis . Also the very limited 
knowledge of functional effects of CFTR mutated alleles 
severely impairs our diagnostic and prognostic ability. The 
final phenotypic modulation exerted by CFTR modifier 
genes and interactome further complicates the framework. 
The next generation sequencing approach is a rapid, low-
cost and high-throughput tool that allows a near complete 
structural characterization of CFTR mutated genotypes, as 
well as of genotypes of several other genes cooperating to 
the final CF clinical manifestations. This powerful method 
perfectly complements the new personalized therapeutic 
approach for CF. Drugs active on specific CFTR mutational 
classes are already available for CF patients or are in 
phase 3 trials. A complete genetic characterization has 
been becoming crucial for a correct personalized therapy. 
However, the need of a functional classification of each 
CFTR mutation potently arises. Future big efforts towards 
an ever more detailed knowledge of both structural and 
functional CFTR defects, coupled to parallel personalized 
therapeutic interventions decisive for CF cure can be 
foreseen. 
Key words: Genotype - phenotype relationship; CFTR; 
Cystic fibrosis; Next generation sequencing; Functional 
meaning of mutations; Personalized therapy; Mutation 
search; Mutation functional classes
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Core tip: Cystic fibrosis (CF) is the most common severe 
monogenic disease of Caucasian population. Despite its 
apparently simple genetics, it has a complex genotype 
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- phenotype relationship. This is mainly due to the high 
number of mutations of the causing gene (the CFTR) 
and to the complexity of the CFTR  cellular network. 
The next generation sequencing approach allows a full 
genetic characterization of the CFTR and CFTR network 
improving our diagnostic, prognostic and therapeutic 
ability. This is coupled to the availability of drugs acting 
on specific mutational classes. The synergy between 
massive sequencing and personalized therapy is expected 
to produce an unparalleled advantage for CF patients. 
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INTRODUCTION
Cystic fibrosis (CF; OMIM 219700) has a variable incidence, 
mostly from 1/25000 (but even with lower incidences in 
some Countries) to 1/900, depending on the geographical 
region considered[1-3], and a high heterogeneity of its 
mutational spectrum and clinical manifestations[3-6]. It 
is considered the most common lethal genetic disease 
of the Caucasian population, with an average incidence 
among Europeans and white Americans of about 1/3000 
(about 1/27 carriers). The estimated number of affected 
individuals and carriers worldwide is, respectively, at least 
70000 and 20 millions. CF has an autosomal recessive 
inheritance pattern and is caused by mutations of the 
cystic fibrosis transmembrane conductance regulator 
(CFTR; 7q31.2; RefSeq NG_016465.4) gene[7,8] (Figure 1). 
It encodes for a protein expressed mainly at the apical 
membrane of epithelial cells but also in some cells of 
nonepithelial origin. The cftr protein has a primary function 
of chloride ion (Cl-) channel but with several additional 
functions as, for example, the transport of other anions 
(mainly bicarbonate, HCO3-), the regulation of other ionic 
channels (mainly the epithelial channel of sodium ion, 
Na+; ENaC) and a direct or indirect role in immunity and/
or inflammation[7,9,10]. The direction of the Cl- movement 
depends on the specific cell type. For example, the cftr 
channel accomplishes Cl- extracellular secretion in colon 
and airways (Figure 1) but its reabsorption in sweat 
glands[9,10]. 
The most critical effects on morbidity and mortality 
arise in the lung, where a cftr functional deficiency 
originates an anomalous dual ion transport, depending on 
the cftr channel for Cl- secretion and on the regulation of 
enac channel for Na+ reabsorption[11-15]. The consequent 
altered water absorption produces a sticky mucus and 
an abnormally viscous airway surface fluid which leads 
to impaired mucociliary clearance[8]. Bacterial infections, 
often multiresistant, and an exacerbated response of 
immune system produce bronchial obstruction, bron-
chiectasis, atrophy and, finally, respiratory failure[8,16]. 
Clinical manifestations and severity of CF are highly 
variable. Classic CF forms and CFTR-related disorders 
(CFTR-RDs, also called non-classic forms) are generally 
recognized[17,18]. The classic CF is usually poly-sympto-
matic and multi-organs, with infertility for obstructive 
azoospermia due to congenital bilateral absence of vas 
deferens (CBAVD) in nearly all CF male and pancreatic 
insufficiency in over 80% of patients. The CFTR-RDs are 
usually oligo- or even mono-symptomatic with more than 
10 different and highly heterogeneous phenotypes[7]. 
The most characterized CFTR-RDs are probably those 
linked to male infertility and subfertility. By now, the 
mono-symptomatic CBAVD (with no other symptoms of 
CF) is a clinical entity well known to be based on CFTR 
mutations in a considerable proportion of cases[5,6,19]. 
Other male reproductive defects, such as non-obstructive 
azoospermia, reduced sperm quality, spermatogenesis 
defects[20-26] and idiopathic seminal hyperviscosity[27,28], 
have been proposed to be linked to CFTR mutations in 
at least part of cases, and deserve further studies. Other 
well-defined CFTR-RDs are idiopathic pancreatitis and 
disseminated bronchiectasis[6]. 
The CF diagnosis needs the combination of CFTR genetic 
analysis, biochemical assessment (the main diagnostic test 
being sweat test[29]) and clinical presentation, according 
to recent guidelines and recommendations[17,18]. However, 
several variables complicate the framework.
A MONOGENIC DISEASE WITH A 
COMPLEX GENOTYPE - PHENOTYPE 
RELATIONSHIP
The genomic sequence of CFTR gene is about 250 kb 
long and contains 27 exons. The main transcript is 
of 6132 bases and is translated to a protein of 1480 
aminoacids (Ensembl database http://www.ensembl.org/
index.html). CF should have a simple genetics. Affected 
subjects have both mutated alleles, with the same 
(homozygotes) or different (compound heterozygotes) 
mutations. A carrier of one mutation on one allele has no 
clinical symptoms. Two carriers have a risk of 1/4 (25%) 
of having an affected child. However, several biochemical 
and genetic aspects add complexity. 
At moment 2011 CFTR sequence variations are 
identified (CFTR1 database http://www.genet.sickkids.
on.ca/Home.html). Although a great effort directed to 
the recognition of CFTR disease-causing mutations[5,30] 
(CFTR2 database http://cftr2.net/) is underway, pathogenic 
consequences are known only for a part of them. CFTR 
mutations that have been functionally characterized are 
grouped into 6 mutational classes[6,31] (Table 1). The 
class Ⅰ (defective synthesis) identifies mutations with a 
complete lack of protein production. Most of the mutations 
in class Ⅰ are nonsense, frameshift or severe splicing 
mutations, as well as deletions or insertions. In the class 
Ⅱ (defective processing and trafficking) are grouped 
processing/maturation defects with increased degradation, 
within the endoplasmic reticulum, of the misfolded protein 
and a severe decrease of the protein quantity in the apical 
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membrane. In class Ⅲ (defective regulation or gating) 
are included mutations leading to a defective regulation 
that impair channel opening. In class Ⅳ (defective Cl- 
conductance) are grouped the defects of reduced Cl- 
transport through the cftr channel. Most of the mutations 
in classes Ⅱ, Ⅲ or Ⅳ are missense mutations (but also 
small deletions or insertions can be found). Class Ⅴ 
(reduced synthesis) mutations are mild to moderate 
splicing defects, promoter mutations or, in general, 
mutations that by various mechanisms reduce the wild 
type mRNA. Class Ⅵ (decreased stability) mutations 
decrease the stability of cftr protein in membrane. 
Mutations producing a reduced CFTR ability in regulating 
other ionic channel are usually classified into this class. 
They can be missense mutations but also nonsense or 
frameshift mutations of the cftr C-terminus (for example 
generating overdue stop codons). Frequently, one mutation 
can raise more than one biochemical defect and, con-
sequently, can be classified into different mutational 
classes. For example, the most common CFTR mutation, 
the F508del, belongs to at least 3 different classes. It mainly 
acts as a class Ⅱ mutation, but also as a class Ⅲ and Ⅴ. In 
CF patients, mutations can combine in trans (on different 
alleles) to originate a great number of homozygous and 
compound heterozygous mutated genotypes. However, it is 
becoming clear that also combinations of mutations in cis (on 
the same allele) are not uncommon. 
Mutated genotypes of patients with varying clinical 
forms of CF may appear identical, despite the presence of 
in cis mutations and/or sequence variations not revealed. 
This usually happens for the incompleteness of diagnostic 
mutational search protocols that are often stopped 
after the finding of the first two CFTR mutations in trans. 
Although a focused experimental search for complex 
alleles has not yet been undertaken, about 50 of them 
have been so far described[7,32]. A complex allele is often 
originated by mutations that have a mild phenotypic effect 
if isolated but, if combined in cis, originate more severe 
Mutation class Functional effect Structural defect Mutation-specific intervention Personalized therapy
Ⅰ    Defective protein synthesis (complete 
lack of protein production)
Nonsense mutations Restore synthesis by 
suppressors of premature stop 
codons in-frame (read-through 
drugs)
Suppressor in phase 3 trials: 
AtalurenFrameshift mutations
Severe splicing mutations
Deletions or insertions 
(a common mechanism is the 
onset of premature stop codons)
Ⅱ Defective protein processing and/
or trafficking (severe decrease of 
protein in the apical membrane due 
to processing and/or maturation 
defects)
Missense mutations
Small deletions or insertions
Restore processing and 
trafficking by correctors 
(chemical, molecular, 
pharmacological chaperones) 
and combined approaches 
(corrector + potentiator)
Combined therapy to patients: 
Orkambi (the corrector 
Lumacaftor + the potentiator 
Ivacaftor)
Ⅲ Defective channel regulation and/or 
gating (impaired channel opening)
Missense mutations Restore channel regulation and 
gating by potentiators
Potentiator to patients: 
IvacaftorSmall deletions or insertions
Ⅳ Defective Cl- conductance (reduced 
Cl- transport through the channel)
Missense mutations Restore the Cl- conductance by 
potentiators
Under evaluation
Small deletions or insertions
Ⅴ Reduced mRNA synthesis (reduction 
of the wild type mRNA)
Partial splicing mutations
Promoter mutations
Restore wild-type mRNA levels 
by correctors, potentiators and/
or antisense oligonucleotides
Under evaluation
Ⅵ Decreased protein stability in 
membrane or reduced ability of other 
channel regulation
Missense mutations Restore stability and regulation 
ability by potentiators, 
stabilizers and/or suppressors 
of overdue stop codons 
in-frame
Under evaluation
Nonsense mutations
Frameshift mutations
(a common mechanism is the 
onset of overdue stop codons 
because of mutations of the 
protein C-terminus)
Table 1  Cystic fibrosis transmembrane conductance regulator mutation classes and cystic fibrosis personalized therapy
Cl- (chloride) 
transport
TMD1
Cell exterior
Cell surface 
(membrane)
Cell interior
TMD2
NBD2
NBD1
Regulatory domain
Schematic 
rendering of CFTR
Figure 1  Schematic representation of cystic fibrosis transmembrane 
conductance regulator protein. Image from Johns Hopkins Cystic Fibrosis 
Center website: http://www.hopkinscf.org/what-is-cf/basic-science/cftr/structure/. 
TMD: Transmembrane domain; NBD: Nucleotide-binding domain; CFTR: Cystic 
fibrosis transmembrane conductance regulator.
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clinical symptoms. Also cases of one main mutation whose 
phenotypic effect is worsened by a second sequence 
variation characterized as neutral if isolated have been 
described. Even cases of additional mutations in cis that 
lessen the phenotypic severity exist. Furthermore, it has 
been demonstrated that some CFTR polymorphisms 
combined in specific haplotypes may have mild clinical 
consequences[33,34]. 
CFTR transcription is controlled in a time- and tissue-
specific manner[10], with regulatory elements not limited 
to its own promoter but extended to the whole CFTR 
locus[35-39], which encompasses about 500 kb of genomic 
DNA. Also miRNAs have been shown to contribute to final 
CFTR mRNA levels[40-44]. Within the path from the gene 
to the channel acting in cell membrane, the cftr protein 
undergoes complex processes of transport and maturation, 
channel opening and closing (as well as its other multiple 
functions), endocytosis and recycling, interaction with 
several other membrane proteins and, finally, degradation 
within lysosomes[10,45,46]. Several experimental evidences 
highlighted the modulation of the direct effects of 
CFTR, either wild type or mutated, by other genes. A 
common evidence of this effect is a high clinical variability 
between CF patients with a really identical CFTR mutated 
genotype. This property is usually attributed to the so-
called modifier genes[47] or, more generally, to the CFTR 
interactome[48]. A number of independent studies dealt with 
this topic and tens of genes candidate to the modulation 
of original cftr effect have been selected[6,47,49-54]. The last 
investigation of the International Cystic Fibrosis Gene 
Modifier Consortium[55] is considered the most complete 
one at moment. They explored over 8 million variants in 
an overall number of 6365 CF patients by two genome-
wide association studies. Five modifier loci of lung disease 
severity have been found highly significantly associated 
with the severity of lung disease in CF patients. The need 
of replication studies aimed to the consolidation of the 
original findings is at moment particularly felt. 
Due to the above mentioned sources of variability, 
and also to random variability and environmental 
influences, the genotype - phenotype relationship in CF 
is very complex[54,56]. This complexity severely hampers 
our diagnostic, prognostic and therapeutic abilities. 
Although few, if any, direct experimental data exist, it is 
generally accepted that the clinical manifestations and 
severity depend on cftr residual function[57,58] which, in 
turn, depends on the sum of the events that, directly or 
indirectly, determine cftr overall functionality. Furthermore, 
the cftr levels physiologically required are tissue-specific, 
which means that at the same level of functional cftr 
only some organs will be affected. The general model 
of residual functionality cannot be easily translated into 
clinical practice, mainly for our poor understanding of all 
molecular mechanisms involved. The common sentence 
that “genotype - phenotype relationship in CF is unclear” 
appears to be supported only by our limited knowledge of 
molecular pathogenesis of this disease. Every effort aimed 
to an enhanced structural and functional characterization 
of CFTR gene and mutations, as well as of all the other 
involved genes, is welcomed.
A first step towards a more functional view of CF is the 
moving from an allele-oriented to a genotypic-oriented 
view of CFTR genetics[5]. The whole CFTR mutated geno-
type, taking into account all the mutations both in trans 
and in cis present in each patient, appears to be an 
enhanced descriptor of the final clinical form, at least at 
level of phenotypic macro-categories. In agreement with 
this enhanced view, also the CFTR2 database has been 
recently improved towards the analysis of genotypes, in 
addition to the classic allelic view. 
NEXT GENERATION SEQUENCING AND 
FUNCTIONAL MEANING OF MUTATIONS
The complex genetics and genotype - phenotype rela-
tionship which underlies CF has been complicating the 
delineation of unequivocal mutation search strategies. It 
has been proved that it is not possible to set up a unique 
genetic test suitable for both diagnostic (including the 
mutational search step of neonatal screening programs) 
and carrier screening programs directed to the general 
population, as well as for all clinical forms of CF[59]. For 
diagnostic purpose, a multistep genetic approach is usually 
applied[5,59]. The first step commonly used is the search for 
a panel of mutations showing a suitably high detection rate 
(the proportion of mutated alleles detectable by the specific 
test; DR). Notably, there is no limitation regarding the 
type of mutations that can be included in panels. In fact, 
recently, also well characterized (particularly concerning 
the breakpoints) and frequent CFTR macro-deletions 
have been included. Depending of the geographical area 
and on the CF clinical form, the DR may vary greatly and, 
if the same panel is anyhow used, a number of alleles with 
no mutation detected (the so-called “unknown” alleles) 
remain. In these cases, a second step of sequencing, 
usually of all the exons, adjacent intronic zones and pro-
ximal 5’-flanking of CFTR gene, is often applied. The DR 
reached is considerably increased in respect to the first 
step, although some molecular lesions are not recognized 
yet as, for example, full intronic mutations and copy 
number variations (CNVs, mainly rare macro-deletions and 
macro-duplications of CFTR gene). To this purpose, a third 
step of search for CNVs is added for all those subjects with 
CF suspect but still with unknown alleles at the second 
step. Only in a very small proportion of cases a fourth step 
of RNA analysis (able to reveal anomalous splicing caused 
by full intronic mutations) is further added[60]. Furthermore, 
the common multistep approach is ending the mutational 
search on CFTR after the first two mutations in trans are 
found. This can often represent a severe limitation of 
the accuracy of CFTR genotyping, but can be seen as an 
unavoidable consequence of the use of mutational panels.
It is obvious that the multistep approach is inappro-
priate for carrier screening. The best mutational panel, 
optimized for ethnic origin of the tested subject and for 
the clinical form the program is aimed to, should be 
used. This seems to be appropriate even if only classic 
Lucarelli M. New era of cystic fibrosis
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CF is within the carrier screening program, as differences 
between mutational patterns underlying different clinical 
manifestations of classic CF (for example pancreas 
sufficiency and insufficiency) have been highlighted[59]. 
The so-called next generation sequencing (NGS) is 
a first revolutionary hit, breaking the CFTR mutational 
search field[61-65] (Table 2). The possibility to sequence a 
huge number of extended DNA zones, rapidly and at low-
cost, will allow the sequence analysis of CFTR regions 
usually not studied as, for example, the distal 5’-flanking, 
the 3’-UTR and the full introns, as well as the whole CFTR 
locus. It probably will also reveal an unsuspected high 
number of complex alleles. In addition, as at least some 
NGS platform also allows the simultaneous analysis of 
small mutations as well as CNVs, a combination of the 
second and third step of genetic analysis in a single step 
is expected. Even the actual possibility of a complete 
sequence analysis of genes of CFTR interactome is at 
hand, allowing a full analysis of both intra-CFTR and CF-
related extra-CFTR structural variability. This approach 
raises the problem, common to every sequencing protocol 
but enhanced by the effect of scale of the massive parallel 
sequencing, of functional interpretation of the huge number 
of sequence variations found. 
The ability of NGS approaches to find sequence 
variations greatly overcomes our ability of their functional 
characterization for clinical purposes. This problem is 
doomed to increase in parallel with the finding of an 
increasing number of complex alleles and of sequence 
variations both within the CFTR locus and in the net-
working genes of CFTR interactome. Although complex 
alleles are at moment barely studied from functional 
point of view, some demonstration of their effect on the 
final phenotype exists[66,67] (for a review see[7,32]). On the 
contrary, only sporadic, if any, attempts have already been 
made to demonstrate long-range regulation alterations by 
sequence variations within CFTR locus as well as to reveal 
some perturbations of the CFTR interactome coordination 
by sequence variations in the cooperating genes. 
Mainly due to these interpretation limitations, it is 
likely that mutational search by panels of mutations 
already characterized as disease-causing will persist. 
Also in this case, NGS approaches can greatly enhance 
our mutational search ability allowing the use of wider 
mutational panels. It is now possible to include in NGS 
panels hundreds of disease-causing mutations of CFTR 
gene, including complex alleles. Thanks to the increasing 
number of mutations of NGS panels, the gap at moment 
observed between the DR shown by the same mutational 
panel applied to different ethnicities and CF clinical 
forms[59] will reduce. However, due to the existence of 
very rare, and often individual, mutations[5] and of a 
high geographical heterogeneity, it is unlikely that only 
one large panel can be suitable for all ethnicities and CF 
clinical forms. 
PERSONALIZED THERAPY
The availability of a methodological approach potentially 
able to recognize all the molecular lesions relevant 
for the clinical manifestation of CF perfectly fits with 
the P4 medicine framework: Personalized, predictive, 
preventive and participatory[68,69]. 
A second revolutionary hit in CF, which completely 
changed the therapeutic mindset, was the demonstration 
that the personalized therapy of CF is not anymore 
just a vision. At moment, in CF, the term personalized 
therapy mostly means the correction of the effects of 
specific CFTR mutations by a small-molecule therapy 
targeting the defective cftr protein (Table 1). The work 
of categorizing CFTR mutations in functional mutational 
classes according to their biochemical effects, which 
could appear only an academic exercise, revealed to be 
fundamental for the development of effective therapies[70]. 
Nineteen treatments aimed to the restoration of cftr 
function depending on the kind of mutations are at mo-
ment in the drug development pipeline of the United 
States CF Foundation (https://www.cff.org/Trials/Pipeline). 
Feature Classic approach NGS approach
Analytical requirements for a full characterization 
of the CFTR gene
Multiple technical steps and different analytical 
platforms
Reduced number of technical steps and single 
analytical platform
Data elaboration Multiple data elaboration steps handled by the 
laboratory itself
Reduced number of data elaboration steps often 
performed by internal dedicated personnel or 
external structures
Throughput Low High
Automation Moderate High
Timing Time consuming Rapid
Cost per sample High Low (if a reasonably high number of samples are 
processed in the same run)
No. of mutations analyzed Progressively increasing from moderate (first 
steps) to high (last steps)
High
Detection rate Progressively increasing from moderate (first 
steps) to high (last steps)
High
Possibility to analyze other genes involved in the 
modulation of CF clinical manifestations
Unlikely Realistic
Table 2  Comparison of classic and next generation sequencing approaches for diagnostic mutation search in cystic fibrosis
NGS: Next generation sequencing; CF: Cystic fibrosis; CFTR: Cystic fibrosis transmembrane conductance regulator.
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Two mutational class-specific treatments are now in 
clinical practice. The first is the Ivacaftor (also known 
as VX-770 or Kalydeco), a potentiator facilitating the 
opening of the Cl- channel in the cell membrane, re-
leased to patients in December 2014. It is effective on 
the so-called mutations of gating and was approved 
for 9 specific mutations belonging to this class. The 
second is a therapy that combines a corrector and a 
potentiator, respectively, the Lumacaftor (also known as 
VX-809) and the Ivacaftor (the combined therapy is also 
known as Orkambi), released to patients in July 2015. 
It is effective also on those mutations with a defective 
maturation as, for example, the F508del. In addition to 
these drugs already approved for clinical use, there are 
also 2 drugs in phase 3 trials: The Ataluren (Translarna), 
which is effective on nonsense mutations by overriding 
the premature stop signal, and the combined therapy 
of Tezacaftor (also known as VX-661) and Ivacaftor 
(respectively, a corrector and a potentiator). Another 
seven drugs are in phase 2 trials and another two in 
phase 1 trials. Finally, six drugs are in pre-clinical studies. 
The CF personalized therapy is effective for few mutations 
but is upcoming for a larger number of them[71-75]. 
The NGS approach greatly facilitate the task of 
mutation finding, also taking into account the possibility 
of multiple molecular lesions concomitantly defining the 
final severity of the disease and its multifaceted clinical 
manifestations. It should be evident that an inaccurate 
mutated genotype, not recognizing all co-occurring mo-
lecular lesions, may severely hamper the therapeutic 
response to a mutation-specific therapy, also with economic 
drawback due to their high cost. However, despite the 
increased ability of mutation finding, the obstacle of 
functional characterization of sequence variations found will 
probably persist for some time. A central point of future CF 
molecular genetics is the assessment of disease liability of 
all the CFTR mutations, rare variants included[76]. Without 
a full comprehension of the biochemical mechanism of 
each mutation or, at least, the assignment to a functional 
class (a concept that should be extended to all DNA 
regions and genes involved) a personalized therapy would 
be unsuitable. In addition, the possibility of biochemical 
defects in multiple mutational classes for the same 
mutation should be taken into account. To deal with this 
tasks, it has been proposed to evaluate CFTR sequence 
variations, in cell-based studies, according to the effect 
on cftr protein of therapeutic drugs and, consequently, to 
classifying them in “theratypes”. An enhanced knowledge 
of CFTR genetics reached thanks to NGS approaches is 
a relevant step that could allow the physician to apply 
a predictive medicine able to delineate the possible 
evolution of CF, as well as a preventive medicine able to 
deliver a personalized therapy early enough to reduce at 
minimum, or even to completely overcome, the clinical 
manifestations. 
A comparison between cftr protein therapy and CFTR 
genetic medicine is unavoidable. Gene therapy, mRNA 
therapy, gene repair and mRNA repair are the genetic me-
dicine strategies usually recognized for CF[77]. At present, 
the gene therapy is the most advanced genetic medicine 
approach for this disease. It should however be clear that 
the cftr protein therapy is a reality whereas the CFTR 
gene therapy is a hope. About 27 clinical trials of gene 
therapy involving approximately 600 CF patients have 
been completed. Currently, only the UK CF Gene Therapy 
Consortium (http://www.cfgenetherapy.org.uk/) is active 
in gene therapy trials for CF. The state-of-the-art is the 
most recent non-viral phase 2b multi-dose trial that, for 
the first time, demonstrated the possibility of stabilizing 
the progression of CF lung disease[78]. A characterizing 
aspect of the present personalized medicine acting on 
cftr protein defects is its restriction to specific mutations 
or, at least, mutational classes. Each drug is effective only 
on a limited number of mutations possibly belonging to 
the same class, highly characterized in their biochemical 
mechanism of action. The delivery of these drugs is 
not restricted to the lung and can complement multi-
organ defects common in CF. However, continuous drug 
administration is required and the physiological level of 
cftr functionality is not restored. On the contrary, the 
gene therapy can in theory complement any CF mutation 
without the need of a deep knowledge of its biochemical 
mechanism of action, the correction could be more 
stable over time and could reach physiological level of 
cftr functionality. However, the delivery of therapeutic 
sequence cannot be as generalized as for drugs and 
a multi-organ complementation is currently unreal. 
Usually, the lung is the target organ although the efficient 
delivery of therapeutic sequence to lung airway epithelial 
cells remains a very hard task, because of a dramatically 
altered composition of airway surface fluid and the 
presence of thick mucus. 
The improvement of classic symptom-based treat-
ments, together with dedicated Centers for the cure 
and multidisciplinary teams, have been warranting an 
increasing of the survival median of CF patients from 
few years (if not months) in the 1930s up to about 40 
years according to a projected median survival for children 
born and diagnosed in 2010. A further amazing elevation 
of life expectancy is predictable following personalized 
therapy. In the meantime gene therapy will be able to 
solve the basic defect of the disease. 
CONCLUSION
CF is more complicated than expected. NGS platforms 
represent a revolutionary experimental approach allowing 
the mutational search in CFTR gene and CFTR gene 
network with unprecedented power. Within next years 
an effort towards a full knowledge of the CFTR gene 
and CFTR locus structure together with related long-
range interactions, as well as of CFTR locus mutations 
in cis and trans is expected. This will help moving to a 
genotypic-oriented view of CFTR genetics. Replication 
studies defining what are the effective modifier genes in 
CF, outlining their exact role and revealing the sequence 
variations that disrupt the CFTR interactome coordination 
is also needed. All these aspects will contribute to an 
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enhanced comprehension of the genotype - phenotype 
relationship in CF. Also the possibility of a real clinical 
application of the personalized therapy aimed to 
the correction of the biochemical defects of specific 
mutational classes has been arising in a likewise 
revolutionary manner. For the widest application of the 
personalized therapy in CF, the functional characterization 
at biochemical, cellular and clinical level of the huge 
number of CFTR sequence variations that will be found 
is mandatory. The area of functional characterization 
of CFTR gene and CFTR locus mutations will probably 
be the most intensively pursued in the next future. The 
synergy between the two ground-breaking novelties 
of massive sequencing and personalized therapy is 
expected to produce an unparalleled advantage for CF 
patients. Without forgetting that CF is a genetic disease 
and a definitive correction of its molecular causes only 
can come from genetics.
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